Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1651 1652 1656 1761
This examiner grants 58% of resolved cases
David J. Steadman is a patent examiner in Tech Center 1700 and Art Unit 1651. He has a substantial record of 971 resolved cases. The examiner maintains an allowance rate of 57.7 percent, which indicates the frequency at which applications reach issuance. This percentage provides a baseline for practitioners to evaluate the probability of a grant when assigned to this examiner.
The median time to allowance is 1145 days. This figure represents the typical duration for the prosecution cycle for successful applications. Practitioners can use this 1145 day median to plan their intellectual property strategy and manage expectations regarding the speed of the process. The 971 resolved cases provide a robust foundation for this temporal metric.
The data also shows an interview lift of 29.6 percent. This significant lift indicates that direct communication with the examiner is a very effective tool for increasing the chances of an allowance. The 29.6 percent figure suggests that interviews are a key tactical recommendation for overcoming rejections. These combined metrics define the examination environment for applicants in Art Unit 1651.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17295198 | METHOD FOR THE PRODUCTION OF ENZYMES BY A STRAIN BELONGING TO A FILAMENTOUS FUNGUS | Final Rejection | IFP Energies nouvelles |
| 18799804 | FIBRIN COMPOSITION, SUBSTRATE FOR REGENERATIVE MEDICINE, METHOD FOR MANUFACTURING FIBRIN COMPOSITION, AND KIT | Non-Final OA | FUJIFILM Corporation |
| 18501324 | DETERGENT COMPOSITIONS CONTAINING A XYLOGLUCANASE AND A HUEING DYE | Final Rejection | The Procter & Gamble Company |
| 18325455 | DISHWASHING DETERGENT COMPOSITION COMPRISING XYLANASE AND SULPHONATED CARBOXYLATE POLYMER | Non-Final OA | The Procter & Gamble Company |
| 18297302 | CLEANING COMPOSITIONS CONTAINING ALGINATE LYASE ENZYMES | Final Rejection | The Procter & Gamble Company |
| 18027461 | Improved Combination of Protease and Protease Inhibitor with Secondary Enzyme | Non-Final OA | BASF SE |
| 17774463 | METHOD OF STORING A BIOCATALYST | Non-Final OA | BASF SE |
| 18242018 | WASHING AND CLEANING AGENTS COMPRISING TANNASE I | Final Rejection | Henkel AG & Co. KGaA |
| 18262832 | AMYLASE VARIANTS | Final Rejection | HENKEL AG & CO. KGAA |
| 16756134 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18070633 | Noscapinoid-producing Microbes and Methods of Making and Using the Same | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17334055 | MINIMAL PEPTIDE FUSIONS FOR TARGETED INTRACELLULAR PROTEIN DEGRADATION | Non-Final OA | Massachusetts Institute of Technology |
| 17968818 | PROTEIN COMPOSITION WITH ISOPRENE POLYMERIZATION ACTIVITY AND APPLICATION THEREOF | Final Rejection | Sumitomo Riko Company Limited |
| 18467658 | Method for Cell Line Development | Final Rejection | Cytiva Sweden AB |
| 18718517 | MIXTURES OF GLUCOSE AND XYLOSE FOR THE FERMENTATIVE PREPARATION OF ORTHO-AMINOBENZOIC ACID | Non-Final OA | Covestro Deutschland AG |
| 18094973 | NEIL2 PROTEIN THERAPY FOR TREATMENT OF VIRAL INFECTION | Non-Final OA | Board of Regents, The University of Texas System |
| 17625883 | METHOD FOR LOADING OF MICROORGANISMS ON MULTIPHASE BIOMATERIALS | Final Rejection | Evonik Operations GmbH |
| 18832145 | DNase Variants and Compositions | Non-Final OA | Novozymes A/S |
| 18318442 | DETERGENT COMPOSITION COMPRISING LACCASE | Non-Final OA | Novozymes A/S |
| 18318470 | Detergent Composition Comprising Laccase | Non-Final OA | Novozymes A/S |
| 18864602 | PROCESS FOR PRODUCING L-CYSTEIC ACID AND USE THEREOF | Non-Final OA | WACKER CHEMIE AG |
| 18841441 | IMPROVED CYSTEINE-PRODUCING STRAINS | Non-Final OA | WACKER CHEMIE AG |
| 17838741 | Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease | Final Rejection | Amicus Therapeutics, Inc. |
| 18812371 | ENHANCEMENT OF KINASE TARGET ENGAGEMENT | Non-Final OA | Promega Corporation |
| 18145608 | NEOPINONE ISOMERASE AND METHODS OF USING | Non-Final OA | Antheia, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy